Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Few patients with triple negative breast cancer (TNBC) benefit from immune checkpoint inhibitors with complete and durable remissions being quite rare. Oncogenes can regulate tumor immune infiltration, however whether oncogenes dictate diminished response to immunotherapy and whether these effects a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Joyce V., Housley, Filomena, Yau, Christina, Nakagawa, Rachel, Winkler, Juliane, Anttila, Johanna M., Munne, Pauliina M., Savelius, Mariel, Houlahan, Kathleen E., Van de Mark, Daniel, Hemmati, Golzar, Hernandez, Grace A., Zhang, Yibing, Samson, Susan, Baas, Carole, Kok, Marleen, Esserman, Laura J., van ‘t Veer, Laura J., Rugo, Hope S., Curtis, Christina, Klefström, Juha, Matloubian, Mehrdad, Goga, Andrei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237085/
https://www.ncbi.nlm.nih.gov/pubmed/35760778
http://dx.doi.org/10.1038/s41467-022-31238-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237085/
https://www.ncbi.nlm.nih.gov/pubmed/35760778
http://dx.doi.org/10.1038/s41467-022-31238-y

Ejemplares similares